WAT logo

Waters Corporation (WAT)

$449.78

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on WAT

Market cap

$44.21B

EPS

2.32

P/E ratio

108.4

Price to sales

9.18

Dividend yield

--

Beta

1.162742

Price on WAT

Previous close

$453.42

Today's open

$452.04

Day's range

$447.78 - $458.33

52 week range

$282.77 - $483.33

Profile about WAT

CEO

Udit Batra

Employees

7900

Headquarters

Milford, MA

Exchange

New York Stock Exchange

Shares outstanding

98285634

Issue type

Common Stock

WAT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on WAT

Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference

MILFORD, Mass., Nov. 17, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D.

news source

PRNewsWire • Nov 17, 2026

news preview

Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers

WAT gains FDA clearance for two blood cancer diagnostic tests, advancing standardized testing and expanding its clinical diagnostics portfolio.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma

BD OneFlow™ LST and BD OneFlow™ B-CLPD T1 Tests now FDA 510(k)-cleared in U.S. for identifying B-cell non-Hodgkin lymphoma (NHL) Delivers 96.3% sensitivity and 98.2% specificity1 in identifying chronic lymphocytic leukemia (CLL), one of the most common types of NHL All-in-one solution reduces 95% of manual steps,2 delivering workflow efficiency, fast turnaround times, and a reduction in errors MILFORD, Mass., Nov. 10, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

news source

PRNewsWire • Nov 10, 2026

news preview

Waters Expands Proteomics Reach With MOBILion Systems Acquisition

WAT expands its proteomics footprint with the MOBILion acquisition, boosting mass spectrometry capabilities, AI-driven research and clinical testing prospects.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Madison Mid Cap Fund Q3 2026 Portfolio Activity

The Madison Mid Cap Fund (Class I) returned -2.09% in the third quarter, compared to the Russell Midcap Index return of -3.00%. The top five contributors for the quarter were Gartner, Medpace Holdings, Ross Stores, Revvity, and Waters Corporation. The bottom five detractors for the quarter were MKS, Floor & Decor Holdings, Carlisle Companies, Moelis and Co., and Glacier Bancorp.

news source

Seeking Alpha • Nov 6, 2026

news preview

Waters Q3 Earnings Call Highlights

Waters NYSE: WAT reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share of $4.10, as the company cited double-digit organic growth, improving performance in acquired businesses and cost actions that supported profitability.

news source

MarketBeat • Nov 4, 2026

news preview

Jim Cramer Calls Big Tech ‘Millstones' and Names the ‘New Techs' Taking Over

Jim Cramer just declared the companies that supply drug labs and research instruments the true heirs to the data center trade, and three stocks are already beating the NASDAQ-100 by a wide margin this year.

news source

24/7 Wall Street • Nov 4, 2026

news preview

Waters Corporation (WAT) Q3 2026 Earnings Call Transcript

Waters Corporation (WAT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery

Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass spectrometry platform, transforming samples to insights. Accelerates Waters' move into proteomics with research capabilities built for AI foundation and frontier models, pairing the unique speed and resolution of the Xevo™ MRT MS with data generation at the scale needed to power proteomics lab-in-the-loop research via Anthropic MCP and MHS protocol support.

news source

PRNewsWire • Nov 3, 2026

news preview

Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results

Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highlights Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by organic revenue growth of 9% as reported and 10% in constant currency, with acquired business revenue landing slightly ahead of guidance. GAAP EPS of $0.82; Adjusted EPS of $4.10 grew 21% and exceeded guidance.

news source

PRNewsWire • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Waters Corporation

Open an M1 investment account to buy and sell Waters Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in WAT on M1